now do SLU-PP-332
$475.00
SLU-PP-332 is an investigational small-molecule research compound studied for its activity as an estrogen-related receptor (ERR) agonist, particularly ERRα. Within controlled laboratory environments, it is evaluated for its influence on mitochondrial biogenesis, oxidative metabolism, and energy-expenditure signaling pathways.
Unlike incretin or peptide-based metabolic agents, SLU-PP-332 functions through nuclear receptor activation, making it a compound of interest in advanced metabolic and endurance-based research models.
Research Name: SLU-PP-332
Alias: ERRα Agonist
Category: Nuclear receptor metabolic modulator
Primary Research Focus: Mitochondrial function, oxidative metabolism, energy expenditure modeling
Format: Lyophilized powder
Upon reconstitution with an appropriate volume of bacteriostatic water (if applicable to study design), final concentration will vary depending on total diluent added. Researchers calculate concentration using the standard formula:
Total mg in vial ÷ Total mL added = mg per mL
For U-100 insulin syringes (if utilized in protocol design):
1 mL = 100 units
Units required are determined by dividing the desired mg amount by the final mg/mL concentration.
Preparation methods may vary depending on research application and delivery model.
SLU-PP-332 is studied for its potential influence on:
Mitochondrial Biogenesis
PGC-1α pathway signaling
Oxidative phosphorylation dynamics
Cellular ATP production modeling
Metabolic & Energy Expenditure Pathways
Fatty acid oxidation signaling
Skeletal muscle metabolic frameworks
Endurance-capacity modeling
Body-Composition Research
Energy utilization trends
Adiposity modeling
Metabolic rate evaluation
Its nuclear receptor activation mechanism differentiates it from GLP-based or peptide metabolic compounds, positioning it within advanced cellular metabolism research frameworks.
Within structured research environments, investigators may observe:
Dose-dependent variables
Energy-expenditure shifts
Metabolic rate changes
Activity-level fluctuations
Metabolic observations
Body-composition trend variation
Caloric utilization changes
Lipid metabolism marker shifts
Less frequent observations
Mild headache
Transient fatigue
Gastrointestinal discomfort
Monitoring typically focuses on metabolic markers, mitochondrial activity, and endurance-related variables.
Administration Frequency: Varies by study design
Common Study Duration: 4–12 weeks
Titration Strategy: Gradual incremental adjustments to evaluate metabolic response
Researchers commonly avoid combining SLU-PP-332 with other strong metabolic stimulators unless specifically designing additive pathway studies.
Store in a cool, dry environment.
Protect from moisture and excessive heat.
Maintain sterile laboratory handling procedures if reconstituted for protocol use.
